Silver Book Fact

Drug-resistant MRSA expensive to treat

As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.

Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso. Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria. Antimicrob Agents Chemother. 2009; 54(1): 109-15. http://aac.asm.org/content/54/1/109.full

Reference

Title
Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria
Publication
Antimicrob Agents Chemother
Publication Date
2009
Authors
Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso
Volume & Issue
Volume 54, Issue 1
Pages
109-15
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Around $35 billion cost to society from antibiotic resistant infections
    The societal costs of antibiotic resistant infections are around $35 billion each year- this includes the cost of lost wages and premature deaths.  
  • Sepsis in hospitalized patients
    Hospitalized patients with sepsis who survived to 31 days experienced a 16.2% absolute increase in late mortality.  
  • Mortality rate from hospital-acquired pneumonia
    The mortality rate for hospital-acquired pneumonia ranges from 38% to more than 70%.  
  • Infection and related sepsis leading cause of death in noncardiac-ICUs
    Infection and related sepsis/septicemia are the leading cause of death in noncardiac-ICUs, accounting for as many as 60% of deaths.  
  • Significant increase of penicillin-resistant Streptococcus penumoniae
    High-level penicillin-resistant Steptococcus pneumoniae increased 1,000-fold over 17 years.